DRC & Research News

This page shares the latest news in T1D research and DRC’s community.

Get the most recent diabetes research news, delivered straight to your inbox

Could There be More than two Types of Diabetes?

and affects their body. Typically type 1 diabetes is diagnosed in childhood and type 2 diabetes develops later in life. However, a team of researchers in Europe and Asia may have identified another form of diabetes: maturity-onset diabetes of the young or MODY.

According to the researchers, MODY is believed to be “caused by a gene mutation and fueled by a lack of the insulin-stimulating hormone GIP.” Individuals with this condition have a mutation of the gene RFX6. Subjects of the study had typically developed MODY by the time they were 25, were not obese, were not insulin-dependent, and had an autosomal dominant inheritance of diabetes.

The researchers believe that the gene mutation results in the pancreas decreasing its insulin secretion, which is common in individuals with diabetes. However, subjects also had lower levels of the GIP hormone which stimulates and regulates insulin secretion. Researchers are hopeful that the creation of GIP analogs may help to treat MODY.

One challenge they have faced is distinguishing between individuals with type 1 or early-onset type 2 diabetes versus those who may have MODY. Improvements in gene testing and sequencing have allowed them to better identify RFX6 mutations.

As scientists and researchers develop a better understanding of diabetes, its forms, and how it impacts the body, it allows for more personalized treatment options. Individuals can find what works best for their specific type of diabetes and their body’s needs. The Diabetes Research Connection encourages and supports novel studies on type 1 diabetes to expand understanding and treatment approaches. Early career scientists receive up to $50,000 in funding for research projects. Learn more about current projects and how to support these efforts by visiting http://diabetesresearchconnection.org.

Learn More +
Insulin inhaler

Inhaled Insulin Powder Now Available in Pharmacies

PInsulin inhalerARIS and VALENCIA, Calif. — Afrezza, an inhaled insulin powder, is now available by prescription in U.S. retail pharmacies, Sanofi and MannKind Corp. announced. The drug is approved by the Food and Drug Administration to control high blood sugar in adults who have type 1 and type 2 diabetes.
Afrezza consists of a dry formulation of human insulin and is administered via a small, portable inhaler to help patients control blood sugar levels. The drug — which the companies said is rapidly absorbed, with a short duration of action — is administered before patients consume a meal.
“Many people living with diabetes are not able to control their blood sugar on their current medications and may benefit from using insulin. Now they have another option to administer insulin that is not an injection,” said Dr. Janet McGill, M.D., professor of medicine at Washington University School of Medicine in St. Louis and Afrezza clinical trial investigator. “This delivery option may help change the dialogue between health care professionals and people living with diabetes about initiating or intensifying insulin therapy.”
The companies noted that Afrezza cannot be used as a treatment for diabetic ketoacidosis, nor should it be used in patients suffering from chronic lung diseases.
Learn More +

Unlimited access to all the essential project updates latest diabetes research news, and more.